【7032】卡非佐米-泊马度胺-地塞米松(KPd)治疗复发/难治性多发性骨髓瘤的有效性和安全性分析:一项来自中国山东省东部的多中心回顾性真实世界研究 Real-World Effectiveness and Safety Analysis of Carfilzomib–Pomalidomide– Dexamethaso...
Sonneveld P,Zweegman S,Cavo M,et al.Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide refractory Multiple Myeloma.Hemasphere . 2022 Sep 30;6(10):e786. doi: 10.1097/HS9.0000000000000786.
[3]Sonneveld P, Zweegman S, Cavo M, et al. Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma [published correction appears in Hemasphere. 2023 Feb 22;7(3):e856]. Hemasphere. 2022;6(10):e786. Published 2022 Sep 30. [4]Perrot ...
The treatment of patients with Multiple Myeloma (MM) with relapse or progressive disease after bortezomib, lenalidomide and high-dose therapy represents an important challenge. In the EMN02 collaborative trial newly diagnosed patients with symptomatic MM were randomized to receive VCD induction followed ...
【4】Richardson P G, Oriol A, Beksac M, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-lab...
4.Sonneveld P, Zweegman S, Cavo M, et al. Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide-refractory Multiple Myeloma [published correction appears in Hemasphere. 2023 Feb 22;7(3):e...
9.Sonneveld P,Zweegman S,Cavo M,et al.Carfilzomib, Pomalidomide, and Dexamethasone As Second-line Therapy for Lenalidomide refractory Multiple Myeloma. Hemasphere. 2022 Sep 30;6(10):e786. 10.Huishou Fanet al. 2024 ...